Saturday 17 October 2026
Export OVID’s income statement to Excel — free account
Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024. In the quarter to June 2026, revenue grew 463.9%, EPS fell 33.3%, free cash flow fell 268.5% and total debt fell 11.7%, each against the same quarter a year earlier.
2.15
0.11
−4.87%
Follow OVID
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
1 | 4 | — | 3 |
| (60.06%) | (17.51%) | (18.77%) | (25.97%) | ||
| (43.64%) | (14.33%) | (15.73%) | (22.30%) | ||
ROIC |
(81.22%) | (36.33%) | (54.88%) | (35.11%) | |
Return on Tangible Assets |
(162.94%) | (26.25%) | (16.71%) | (30.30%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(0.53) | (0.52) | (0.31) | (0.28) | |
Free Cash Flow |
(37.93) | (38.33) | (41.95) | (54.77) | |
| Other line items | |||||
Cash ROIC |
(45.89%) | (18.06%) | (11.48%) | (16.19%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
377.11% | 352.76% | 0.00% | 427.70% | |
Selling, General and Administrative Expense of Revenue |
341.21% | 332.45% | 0.00% | 335.42% | |
Share Based Compensation of Revenue |
73.71% | 66.29% | 0.00% | 60.87% | |
Operating CF/Net income |
1.04 | 2.20 | 1.74 | 1.59 | |
Depreciation/Fixed assets |
1.55 | 1.08 | 0.77 | 0.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.09 | 0.10 | 0.00 | 0.04 | |
Operating CF per Share |
(0.53) | (0.52) | (0.31) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates